Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis

Table of Contents

• 1 Executive Summary
• 2 About Cancer Highlights
• 3 Methodologies
• 4 Table of Contents
  • 4.1 List of Figures
  • 4.2 List of Tables
• 5 How to Use this Report
• 6 Breast Cancer Target Localization
• 7 The Cancer Genome Project and Breast Cancer Targets
  • 7.1 Breast Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
• 8 Protein Expression Profiles of Breast Cancer Drug Targets in Human
  • 8.1 Expression in Normal Tissues and Cancer Tissues
  • 8.2 Expression in Human Cancer Cell Lines and Primary Cells
• 9 Pathway Analysis of Breast Cancer Drugs
• 10 Protein-Protein Interactions Among Identified Breast Cancer Targets
• 11 Available Biological Structure Data on Breast Cancer Targets
• 12 Drug Target Profiles of Breast Cancer Drugs
  • 12.1.1 Catalytic Activity
  • 12.1.2 Cell Adhesion Molecule Activity
  • 12.1.3 Chaperone Activity
  • 12.1.4 Chemokine Activity
  • 12.1.5 Complement Activity
  • 12.1.6 Cysteine-Type Peptidase Activity
  • 12.1.7 Cytokine Activity
  • 12.1.8 DNA Binding
  • 12.1.9 DNA Repair Protein
  • 12.1.10 DNA Topoisomerase Activity
  • 12.1.11 DNA-Directed DNA Polymerase Activity
  • 12.1.12 Glutathione Transferase Activity
  • 12.1.13 G-Protein Coupled Receptor Activity
  • 12.1.14 Growth Factor Activity
  • 12.1.15 Hormone Activity
  • 12.1.16 Kinase Activity
  • 12.1.17 Kinase Binding
  • 12.1.18 Kinase Regulator Activity
  • 12.1.19 Ligand-Dependent Nuclear Receptor Activity
  • 12.1.20 Ligase Activity
  • 12.1.21 Lipid Kinase Activity
  • 12.1.22 Lipid Phosphatase Activity
  • 12.1.23 Metallopeptidase Activity
  • 12.1.24 Molecular Function Unknown
  • 12.1.25 Motor Activity
  • 12.1.26 Oxidoreductase Activity
  • 12.1.27 Protein Binding
  • 12.1.28 Protein Serine/Threonine Kinase Activity
  • 12.1.29 Protein Threonine/Tyrosine Kinase Activity
  • 12.1.30 Protein-Tyrosine Kinase Activity
  • 12.1.31 Receptor Activity
  • 12.1.32 Receptor Binding
  • 12.1.33 Receptor Signaling Complex Scaffold Activity
  • 12.1.34 Receptor Signaling Protein Serine/Threonine Kinase Activity
  • 12.1.35 Serine-Type Peptidase Activity
  • 12.1.36 Structural Constituent of Cytoskeleton
  • 12.1.37 Structural Molecule Activity
  • 12.1.38 Superoxide Dismutase Activity
  • 12.1.39 T Cell Receptor Activity
  • 12.1.40 Transcription Factor Activity
  • 12.1.41 Transcription Regulator Activity
  • 12.1.42 Transferase Activity
  • 12.1.43 Translation Regulator Activity
  • 12.1.44 Transmembrane Receptor Activity
  • 12.1.45 Transmembrane Receptor Protein Tyrosine Kinase Activity
  • 12.1.46 Transporter Activity
• 13 The Drug-Target Interactome
• 14 The Progression and Maturity of Breast Cancer Targets
  • 14.1 Target Profiles of Breast Cancer Drugs in Pre-Registration or on the Market
  • 14.2 New and Unique Breast Cancer Targets in Phase III Clinical Development
  • 14.3 New and Unique Breast Cancer Targets in Phase II Clinical Development
  • 14.4 New and Unique Breast Cancer Targets in Phase I Clinical Development
  • 14.5 New and Unique Breast Cancer Targets in Preclinical Development
  • 14.6 Development Profiles of All Breast Cancer Target Combinations
• 15 Targets by Major Therapy Strategies in Breast Cancer
  • 15.1 Small Molecules
    • 15.1.1 Background
    • 15.1.2 Targets in Breast Cancer
  • 15.2 Peptide/Protein Drugs
    • 15.2.1 Background
    • 15.2.2 Targets in Breast Cancer
  • 15.3 Monoclonal Antibodies and Antibody-Like Structures
    • 15.3.1 Background
    • 15.3.2 Targets in Breast Cancer
  • 15.4 Nucleic Acid Therapies
    • 15.4.1 Background
    • 15.4.2 Targets in Breast Cancer
  • 15.5 Cell and Gene Therapy
    • 15.5.1 Background
    • 15.5.2 Targets in Breast Cancer
  • 15.6 Drug Delivery and Nanotechnology
    • 15.6.1 Background
    • 15.6.2 Targets in Breast Cancer
• 16 Breast Cancer Targets by Companies
  • 16.1 Australia
  • 16.2 Austria
  • 16.3 Canada
  • 16.4 China
  • 16.5 Cuba
  • 16.6 Denmark
  • 16.7 Finland
  • 16.8 France
  • 16.9 Germany
  • 16.10 India
  • 16.11 Ireland
  • 16.12 Israel
  • 16.13 Italy
  • 16.14 Japan
  • 16.15 Netherlands
  • 16.16 New Zealand
  • 16.17 Norway
  • 16.18 South Korea
  • 16.19 Sweden
  • 16.20 Switzerland
  • 16.21 United Kingdom
  • 16.22 USA
  • 16.23 Non-Industrial Bodies
• 17 Disclaimer
• 18 Drug Index
• 19 Company Index

4.1 List of Figures

• Figure 1: Distribution of Compound Types among Breast Cancer Drugs
• Figure 2: Primary Sub-cellular Localization of Drug Targets
• Figure 3: Visualization of Protein-Protein Interactions Among Antibody Drug Targets
• Figure 4: The Drug-Protein Interactome of Breast Cancer Drugs - Main Cluster
• Figure 5: The Drug-Protein Interactome of Breast Cancer Drugs - Smaller Clusters
• Figure 6: Head-to-Head Targeting Interactome of Breast Cancer Drugs

4.2 List of Tables

• Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
• Table 3: Drug Targets of Breast Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
• Table 4: Available Protein Expression Profiles of Breast Cancer Drug Targets
• Table 5: Pathway Summary
• Table 6: Drug Targets without any Identified Assigned Pathways
• Table 7: Pathway Profile According to BioCarta of Breast Cancer Drug Targets
• Table 8: Pathway Profile According to KEGG of Breast Cancer Drug Targets
• Table 9: Breast Cancer Drugs Targeting Major Singaling Pathways
• Table 10: Protein-Protein Interactions among Breast Cancer Drug Targets
• Table 11: Number of Available Biological Structures of Breast Cancer Drug Targets
• Table 12: Overview of Drug Target Profile Themes
• Table 13: Drug-Protein Interactome Clusters
• Table 14: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
• Table 15: Top 5 Pursued Breast Cancer Targets
• Table 16: Target Profiles of Breast Cancer Drugs in Pre-Registration or on the Market
• Table 17: New and Unique Breast Cancer Targets in Phase III Clinical Development
• Table 18: New and Unique Breast Cancer Targets in Phase II Clinical Development
• Table 19 New and Unique Breast Cancer Targets in Phase I Clinical Development
• Table 20: New and Unique Breast Cancer Targets in Preclinical Development
• Table 21: The Progression, Maturity and Competitive Comparison of Breast Cancer Drug Targets in Development
• Table 22: Number of Breast Cancer Drug Target Mixes Reported by Line of Therapy
• Table 23: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Breast Cancer by Drug Target
• Table 24: Drug Targets of Small Molecule Drugs in Breast Cancer
• Table 25: Mechanistic Relationship between Small Molecule Drugs in Breast Cancer
• Table 26: Drug Targets of Peptide Based Drugs in Breast Cancer
• Table 27: Drug Targets of Protein Based Drugs in Breast Cancer
• Table 28: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Breast Cancer
• Table 29: Drug Targets of Nucleic Acid Therapies in Breast Cancer
• Table 30: Potential Forms of Cell Therapy
• Table 31: Vectors in Gene Therapy
• Table 32: Drug Targets of Cell Therapies in Breast Cancer
• Table 33: Drug Targets of Gene Therapies in Breast Cancer
• Table 34: Drug Targets with New Drug Delivery Strategies in Breast Cancer
• Table 35: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Australia
• Table 36: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Austria
• Table 37: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Canada
• Table 38: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in China
• Table 39: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Cuba
• Table 40: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Denmark
• Table 41: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Finland
• Table 42: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in France
• Table 43: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Germany
• Table 44: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in India
• Table 45: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Ireland
• Table 46: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Israel
• Table 47: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Italy
• Table 48: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Japan
• Table 49: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in the Netherlands
• Table 50: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in New Zealand
• Table 51: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Norway
• Table 52: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in South Korea
• Table 53: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Sweden
• Table 54: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Switzerland
• Table 55: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in United Kingdom
• Table 56: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in USA
• Table 57: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Non-Industrial Bodies